Profile data is unavailable for this security.
About the company
Xiamen Amoytop Biotech Co Ltd is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)3.34bn
- Net income in CNY939.58m
- Incorporated1996
- Employees2.42k
- LocationXiamen Amoytop Biotech Co LtdNo.330 Wengjiao RoadHaicang Xinyang Industry ZoneXIAMEN 361028ChinaCHN
- Phone+86 5 926889118
- Fax+86 5 926889130
- Websitehttps://www.amoytop.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.00bn | 4.23k | 1,634.78 | 3.62 | -- | 4.93 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 6.14bn | 1.65bn | 26.13bn | 5.03k | 15.77 | 1.89 | -- | 4.25 | 1.80 | 1.80 | 6.69 | 15.02 | 0.3543 | 2.99 | 3.59 | 1,222,407.00 | 9.53 | 15.19 | 11.67 | 19.57 | 75.44 | 81.73 | 26.91 | 26.02 | 5.18 | -- | 0.0437 | 46.90 | -16.96 | 2.93 | -10.32 | 9.30 | -20.43 | 11.19 |
| Shanghai Junshi Biosciences Co Ltd | 2.48bn | -949.86m | 27.10bn | 2.67k | -- | 4.95 | -- | 10.91 | -0.96 | -0.96 | 2.51 | 6.05 | 0.2203 | 0.8436 | 5.48 | 963,148.80 | -9.45 | -17.61 | -12.31 | -22.00 | 81.59 | 68.46 | -42.92 | -84.56 | 1.43 | -23.04 | 0.3629 | -- | 29.67 | 20.24 | 43.90 | -- | -4.33 | -- |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 5.37bn | 3.58bn | 28.11bn | 3.84k | 8.88 | 3.53 | -- | 5.24 | 4.65 | 4.65 | 6.98 | 11.70 | 0.4758 | 1.35 | 3.16 | 1,399,130.00 | 31.64 | 11.74 | 45.06 | 16.76 | 64.27 | 42.04 | 66.50 | 14.81 | 2.33 | -- | 0.0056 | 54.04 | -11.14 | 0.8791 | 125.94 | 28.94 | -10.54 | 33.67 |
| Xiamen Amoytop Biotech Co Ltd | 3.34bn | 939.58m | 29.90bn | 2.42k | 31.71 | 9.90 | -- | 8.95 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
| Beijing Tiantan Biological Products Corp | 6.42bn | 1.32bn | 31.54bn | 5.30k | 23.96 | 2.75 | -- | 4.91 | 0.6656 | 0.6656 | 3.25 | 5.80 | 0.4002 | 0.9382 | 11.21 | 1,212,453.00 | 11.25 | 11.93 | 16.06 | 16.79 | 45.65 | 50.69 | 28.10 | 29.69 | 3.08 | -- | 0.0152 | 16.24 | 16.44 | 12.94 | 39.58 | 20.45 | 15.19 | 23.56 |
| Humanwell Healthcare Group Co Ltd | 24.18bn | 1.43bn | 31.81bn | 17.65k | 22.30 | 1.68 | -- | 1.32 | 0.8741 | 0.8741 | 14.84 | 11.59 | 0.6519 | 3.63 | 2.48 | 1,369,715.00 | 5.00 | 6.40 | 8.73 | 12.55 | 44.53 | 43.83 | 7.67 | 9.90 | 1.40 | 362.14 | 0.2889 | 25.97 | 3.71 | 3.13 | -37.70 | 11.15 | 4.75 | 56.54 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.37bn | 870.39m | 34.79bn | 995.00 | 40.16 | 5.89 | -- | 25.39 | 1.40 | 1.40 | 2.21 | 9.56 | 0.186 | 1.54 | 4.55 | 1,377,045.00 | 11.66 | 3.14 | 15.35 | 3.34 | 74.88 | 77.37 | 62.65 | 16.95 | 1.97 | -- | 0.00 | 12.57 | 17.70 | 0.2733 | 139.15 | 25.17 | 16.61 | -- |
Data as of Mar 04 2026. Currency figures normalised to Xiamen Amoytop Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
15.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tibet Trust Corp. Ltd.as of 22 May 2025 | 23.19m | 5.70% |
| China Asset Management Co., Ltd.as of 31 Mar 2025 | 8.11m | 1.99% |
| E Fund Management Co., Ltd.as of 31 Mar 2025 | 6.55m | 1.61% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 6.30m | 1.55% |
| Allianz Insurance Asset Management Co., Ltd.as of 31 Mar 2025 | 6.18m | 1.52% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.05m | 0.75% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 3.03m | 0.74% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 2.93m | 0.72% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 1.60m | 0.39% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.50m | 0.37% |
More ▼
Data from 22 May 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
